Using the latest modular workflow technologies, SOM Biotech has released a new version of his proprietary drug repurposing virtual process. This update has had the goal to improve more than 30% the performance, scalability and velocity of the process. This software update highlights the SOM Biotech strong commitment to grow day-by-day, in order to continue…
SOM Biotech releases a new version of its proprietary drug repurposing process
posted on October 19, 2017
Nippon Chemiphar and SOM Biotech to Cooperate on New, Orphan Disease Indications for bevantolol (Calvan®)
posted on October 14, 2017
SOM Biotech has determined and validated an entirely new usage for Nippon Chemiphar’s marketed hypertension therapy bevantolol (Calvan®). SOM, after using a proprietary ligand analysis computational algorithm and completing the preclinical assays, determined that bevantolol (coded SOM3355 by SOM) is a highly effective Vesicular Monoamine Transporter Type 2 (VMAT2) inhibitor, a class of compounds that…
SOM Biotech at 2017 ASEBIO Investor Day
posted on September 26, 2017
SOM Biotech was one of the presenting companies at 2017 ASEBIO Investor Day. ASEBIO Investor Day is an event which allows Spanish innovative biotechnology projects to be introduced to an audience of leading investors and pharmaceutical companies. The event is organized by ASEBIO, the Spanish Bioindustry Association, with the support of ICEX - the Spanish Foreign Trade…
SOM Biotech invited at Chinese-Swiss Health Collaborations Forum
posted on September 18, 2017
SOM Biotech was one of the companies invited to the Private Chinese-Swiss Investor Collaborations Forum that took place in Zurich on September 11th 2017. Dr. Insa (CEO) and Dr. Palazzesi (Senior Computational Chemist) were in charge to present Company’s Strategy and Assets to the large Chinese delegation interested in knowing and investing in health-care EU companies.…
II Workshop sobre Transferencia del Conocimiento Científico en la Distrofia Muscular de Duchenne
posted on September 4, 2017
La Compañía SOM Biotech estuvo presente en el II Workshop sobre Transferencia del Conocimiento Científico en la Distrofia Muscular de Duchenne que se llevó a cabo el pasado día 7 de Septiembre de 2017, día Mundial de dicha enfermedad. Las sesiones tuvieron lugar en el Aula de Grados de la Facultad de Biología de la UB, y en las…
SOM Biotech licenses its first product and expands to the United States
posted on July 25, 2017
The med-tech biopharmaceutical company SOM Biotech, specializing in repurposing drugs to treat rare nervous system diseases, has concluded a worldwide license agreement with Corino Therapeutics Inc. to clinically develop and market the drug SOM0226 against transthyretin amyloidosis (ATTR). Before this licensing agreement had been reached, the drug achieved very promising results in a Phase 2…